T. Treschan and J. Peters, The Vasopressin System, Anesthesiology, vol.105, issue.3, pp.599-612, 2006.
DOI : 10.1097/00000542-200609000-00026

H. Moeller, S. Rittig, and R. Fenton, Nephrogenic Diabetes Insipidus: Essential Insights into the Molecular Background and Potential Therapies for Treatment, Endocrine Reviews, vol.34, issue.2, pp.278-301, 2013.
DOI : 10.1210/er.2012-1044

T. Feinstein, N. Yui, M. Webber, V. Wehbi, H. Stevenson et al., Noncanonical Control of Vasopressin Receptor Type 2 Signaling by Retromer and Arrestin, Journal of Biological Chemistry, vol.288, issue.39, pp.27849-60, 2013.
DOI : 10.1074/jbc.M112.445098

J. Morello and D. Bichet, Nephrogenic Diabetes Insipidus, Annual Review of Physiology, vol.63, issue.1, pp.607-637, 2001.
DOI : 10.1146/annurev.physiol.63.1.607

H. Tsukagushi, H. Matsubara, S. Taketani, Y. Mori, T. Seido et al., Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus., Journal of Clinical Investigation, vol.96, issue.4, pp.2043-50, 1995.
DOI : 10.1172/JCI118252

Y. Ala, D. Morin, B. Mouillac, N. Sabatier, R. Vargas et al., Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus : molecular basis of a mild clinical phenotype, J Am Soc Nephrol, vol.9, pp.1861-72, 1998.

D. Bockenhauer and D. Bichet, Urinary concentration: different ways to open and close the tap, Pediatric Nephrology, vol.103, issue.1977???1978, 2013.
DOI : 10.1007/s00467-013-2526-4

M. Birnbaumer, A. Seibold, S. Gilbert, M. Ishido, C. Barberis et al., Molecular cloning of the receptor for human antidiuretic hormone, Nature, vol.357, issue.6376, pp.333-368, 1992.
DOI : 10.1038/357333a0

S. Lolait, A. Carroll, O. Mcbride, M. Konig, A. Morel et al., Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus, Nature, vol.357, issue.6376, pp.526-555, 1992.
DOI : 10.1038/357336a0

W. Rosenthal, A. Seibold, A. Antaramian, M. Lonergan, M. Arthus et al., Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus, Nature, vol.359, issue.6392, pp.233-268, 1992.
DOI : 10.1038/359233a0

B. Tamarappoo and A. Verkman, Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones., Journal of Clinical Investigation, vol.101, issue.10, pp.2257-67, 1999.
DOI : 10.1172/JCI2303

T. Loo and D. Clarke, Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators, Journal of Biological Chemistry, vol.272, issue.2, pp.709-721, 1997.
DOI : 10.1074/jbc.272.2.709

J. Morello, A. Salahpour, A. Laperrière, V. Bernier, M. Arthus et al., Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants, Journal of Clinical Investigation, vol.105, issue.7, pp.887-95, 2000.
DOI : 10.1172/JCI8688

J. Morello, U. Petäjä-repo, D. Bichet, and M. Bouvier, Pharmacological chaperones: a new twist on receptor folding, Trends in Pharmacological Sciences, vol.21, issue.12, pp.466-69, 2000.
DOI : 10.1016/S0165-6147(00)01575-3

C. Tan, H. Nickols, and L. Limbird, Appropriate Polarization following Pharmacological Rescue of V2 Vasopressin Receptors Encoded by X-linked Nephrogenic Diabetes Insipidus Alleles Involves a Conformation of the Receptor That Also Attains Mature Glycosylation, Journal of Biological Chemistry, vol.278, issue.37, pp.35678-86, 2003.
DOI : 10.1074/jbc.M301888200

S. Wüller, B. Wiesner, A. Loffler, J. Furkert, G. Krause et al., Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors, Journal of Biological Chemistry, vol.279, issue.45, pp.47254-63, 2004.
DOI : 10.1074/jbc.M408154200

D. Bockenhauer, E. Carpentier, D. Rochdi, W. Van-'t-hoff, B. Breton et al., Vasopressin Type 2 Receptor V88M Mutation: Molecular Basis of Partial and Complete Nephrogenic Diabetes Insipidus, Nephron Physiology, vol.114, issue.1, pp.1-10, 2010.
DOI : 10.1159/000245059

J. Janovick, B. Park, and P. Conn, Therapeutic Rescue of Misfolded Mutants: Validation of Primary High Throughput Screens for Identification of Pharmacoperone Drugs, PLoS ONE, vol.29, issue.7, p.22784, 2011.
DOI : 10.1371/journal.pone.0022784.t004

V. Bernier, M. Lagacé, M. Lonergan, M. Arthus, and D. Bichet, Functional Rescue of the Constitutively Internalized V2 Vasopressin Receptor Mutant R137H by the Pharmacological Chaperone Action of SR49059, Molecular Endocrinology, vol.18, issue.8, pp.2074-84, 2004.
DOI : 10.1210/me.2004-0080

V. Bernier, J. Morello, A. Zarruk, N. Debrand, A. Salahpour et al., Pharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes Insipidus, Journal of the American Society of Nephrology, vol.17, issue.1, pp.233-276, 2006.
DOI : 10.1681/ASN.2005080854

J. Robben, M. Sze, N. Knoers, and P. Deen, Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus, AJP: Renal Physiology, vol.292, issue.1, pp.253-60, 2007.
DOI : 10.1152/ajprenal.00247.2006

J. Robben, M. Sze, N. Knoers, and P. Deen, Rescue of Vasopressin V2 Receptor Mutants by Chemical Chaperones: Specificity and Mechanism, Molecular Biology of the Cell, vol.17, issue.1, pp.379-86, 2006.
DOI : 10.1091/mbc.E05-06-0579

J. Janovick, G. Maya-nunez, and P. Conn, Rescue of Hypogonadotropic Hypogonadism-Causing and Manufactured GnRH Receptor Mutants by a Specific Protein-Folding Template: Misrouted Proteins as a Novel Disease Etiology and Therapeutic Target, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.7, pp.3255-62, 2002.
DOI : 10.1210/jcem.87.7.8582

R. Auzan, M. Ventura, and E. Clauser, Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone, J Biol Chem, vol.280, pp.42198-206, 2005.

S. Hawtin, Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V1a Receptor, Journal of Biological Chemistry, vol.281, issue.21, pp.14604-14618, 2006.
DOI : 10.1074/jbc.M511610200

C. Mendre and B. Mouillac, Chaperons pharmacologiques, m??decine/sciences, vol.26, issue.6-7, pp.627-662, 2010.
DOI : 10.1051/medsci/2010266-7627

E. Los, P. Deen, and J. Robben, Potential of Nonpeptide (Ant)agonists to Rescue Vasopressin V2 Receptor Mutants for the Treatment of X-linked Nephrogenic Diabetes Insipidus, Journal of Neuroendocrinology, vol.307, issue.5, pp.393-99, 2010.
DOI : 10.1111/j.1365-2826.2010.01983.x

D. Wesche, P. Deen, and N. Knoers, Congenital nephrogenic diabetes insipidus: the current state of affairs, Pediatric Nephrology, vol.47, issue.Suppl 16, pp.2183-204, 2012.
DOI : 10.1007/s00467-012-2118-8

J. Robben, M. Kortenoeven, M. Sze, C. Yae, G. Milligan et al., Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists, Proceedings of the National Academy of Sciences, vol.106, issue.29, pp.12195-200, 2009.
DOI : 10.1073/pnas.0900130106

F. Jean-alphonse, S. Perkovska, M. Frantz, T. Durroux, C. Méjean et al., Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus, Journal of the American Society of Nephrology, vol.20, issue.10, pp.2190-203, 2009.
DOI : 10.1681/ASN.2008121289
URL : https://hal.archives-ouvertes.fr/inserm-00421838

J. Hanrahan, H. Sampson, and D. Thomas, Novel pharmacological strategies to treat cystic fibrosis, Trends in Pharmacological Sciences, vol.34, issue.2, pp.119-144, 2013.
DOI : 10.1016/j.tips.2012.11.006